238 related articles for article (PubMed ID: 8689858)
1. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL
Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
[TBL] [Abstract][Full Text] [Related]
2. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL; Josse RG; Leiter LA; Mihic M; Nathan DM; Palmason C; Cohen RM; Wolever TM
Diabetes Care; 1996 Nov; 19(11):1190-3. PubMed ID: 8908378
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
4. Effects of acarbose in patients with beta-thalassaemia major and abnormal glucose homeostasis.
Mangiagli A; Campisi S; De Sanctis V; Nicoletti MC; Cardinale G; Galati MC; Raiola G; Rigano P; Saviano A;
Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():276-8. PubMed ID: 16462708
[TBL] [Abstract][Full Text] [Related]
5. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with acarbose as first line therapy in NIDDM.
Fölsch UR
Clin Invest Med; 1995 Aug; 18(4):312-7. PubMed ID: 8549018
[TBL] [Abstract][Full Text] [Related]
8. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
Hasegawa T; Yoneda M; Nakamura K; Ohnishi K; Harada H; Kyouda T; Yoshida Y; Makino I
J Gastroenterol Hepatol; 1998 Dec; 13(12):1201-6. PubMed ID: 9918426
[TBL] [Abstract][Full Text] [Related]
9. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
[TBL] [Abstract][Full Text] [Related]
11. Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance.
Shinoda Y; Inoue I; Nakano T; Seo M; Sassa M; Goto S; Awata T; Komoda T; Katayama S
Metabolism; 2006 Jul; 55(7):935-9. PubMed ID: 16784967
[TBL] [Abstract][Full Text] [Related]
12. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS
Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560
[TBL] [Abstract][Full Text] [Related]
13. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
Liebl A
Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
[TBL] [Abstract][Full Text] [Related]
14. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
Hayakawa T; Noda A; Kondo T; Okumura N
Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
[No Abstract] [Full Text] [Related]
15. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
Eriksson JG; Lehtovirta M; Ehrnström B; Salmela S; Groop L
J Intern Med; 2006 Jun; 259(6):553-60. PubMed ID: 16704555
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
Scheen AJ
Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641
[TBL] [Abstract][Full Text] [Related]
17. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
18. A review of the safety and efficacy of acarbose in diabetes mellitus.
Yee HS; Fong NT
Pharmacotherapy; 1996; 16(5):792-805. PubMed ID: 8888075
[TBL] [Abstract][Full Text] [Related]
19. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
[TBL] [Abstract][Full Text] [Related]
20. Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats.
Yamamoto M; Otsuki M
Metabolism; 2006 Apr; 55(4):533-40. PubMed ID: 16546485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
